Observational studyJournal of endocrinological investigation2026
Risk factors for endocrinological immune-related adverse events in patients with renal cell carcinoma treated with immune checkpoint inhibitors.
Observational study in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Risk factors for immune checkpoint inhibitor-related thyroid dysfunction: a retrospective cohort study.Endocrine · 2026Article
- Pre-treatment endocrine-nutritional signatures predict clinical benefit from PD-1/PD-L1 blockade in hematologic malignancies.Frontiers in nutrition · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeFirst-line treatment for renal cell carcinoma (RCC) commonly includes immune checkpoint inhibitors (ICIs), either as monotherapy or in combination with anti-angiogenic agents. These therapies can lead to endocrine immune-related adverse events (irAEs). This study aimed to identify predictive risk factors for the development of endocrine irAEs associated with ICI-based therapies.
methodsWe conducted an observational, retrospective, single-center study involving 72 patients with RCC who initiated first-line treatment with ICIs (either in combination with another ICI or an anti-angiogenic agent) between January 2018 and May 2023. All patients had at least 18 months of clinical and biochemical follow-up.
results51.39% of patients experienced endocrine irAEs, including thyroid dysfunction (89.2%), primary hypocortisolism (10.8%), and hypophysitis (8.1%). Patients who developed endocrine irAEs had a significantly lower International Metastatic RCC Database Consortium (IMDC) score (p = 0.033), and renal/adrenal metastases were significantly associated with a lower risk of developing endocrine irAEs (p = 0.045) and thyroid dysfunction (p = 0.026). TNM stage II and III at diagnosis were linked with higher rates of endocrine irAEs in males and thyroid dysfunction in the overall population, whereas TNM stage IV was associated with a lower incidence of both outcomes (p = 0.02 and p = 0.05, respectively). In logistic regression analysis of the interaction between stage and sex, TNM stage III was significantly associated with a higher risk of irAEs and thyroid dysfunction in men compared with women at the same stage (p = 0.0184 and p = 0.0301, respectively). Among treatment variables, the use of tyrosine kinase inhibitors (TKIs) emerged as a significant predictor of thyroid irAEs (p = 0.041). A neutrophil percentage below the cohorts' 50th percentile (61.45%) was associated with increased risk of endocrine irAEs (p = 0.048). In multivariate analysis, renal/adrenal metastases and TNM stage IV remained negative predictors of both endocrine irAEs and thyroid dysfunction, while TKI use was a significant positive predictor of thyroid dysfunction.
conclusionsThis study highlights several significant associations between the occurrence of endocrine irAEs and oncological parameters (renal/adrenal metastases, TNM stage), therapeutic factors (use of TKIs), and laboratory markers (neutrophil percentage) in RCC patients. These predictors may be useful in identifying patients who are more likely to develop endocrine irAEs and therefore require more rigorous endocrine surveillance during treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.